Mersana Therapeutics (MRSN) executive Lowinger sold 13,687 shares for $27.2K at an average $1.98 under a 10b5-1 plan
Insider transactions reported
Timothy B Lowinger (SVP, Chief Sci.&Tech. Officer at Mersana Therapeutics Inc., MRSN) reported that they sold 13,687 shares for $27.2K at an average $1.98, and acquired 50,000 shares between Oct 1, 2024 and Oct 3, 2024. After these transactions the filing shows 235,642 shares held directly.
- Reporting person
- Lowinger Timothy B
- Role
- SVP, Chief Sci.&Tech. Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 1, 2024 | Exercise or conversion of a derivative (M) | Common Stock1 | +50,000 | - | - | 249,329 direct |
| Oct 2, 2024 | Open-market sale (S) | Common Stock2, 3 | -8,089 | $2.00 | $16.2K | 241,240 direct |
| Oct 3, 2024 | Open-market sale (S) | Common Stock2, 4 | -5,598 | $1.96 | $11K | 235,642 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Oct 1, 2024 | Exercise or conversion of a derivative (M) | Restricted Stock UnitOn 50,000 Common Stock5, 6 | -50,000 | - | - | 0 direct |
Holdings before and after
- Common Stock: 199,329 to 235,642 direct
- Restricted Stock Unit: 50,000 to 0 direct
Footnotes from the filing
- 1. Represents shares of common stock received upon vesting of the restricted stock units ( RSUs ) awarded to the Reporting Person on September 5, 2023.
- 2. Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic sell to cover transaction that did not represent a discretionary trade by the Reporting Person.
- 3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.82 to $2.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 5. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- 6. Fully vested as of October 1, 2024.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Lowinger report in this MRSN Form 4?
Timothy B Lowinger (SVP, Chief Sci.&Tech. Officer at Mersana Therapeutics Inc., MRSN) reported that they sold 13,687 shares for $27.2K at an average $1.98, and acquired 50,000 shares between Oct 1, 2024 and Oct 3, 2024. After these transactions the filing shows 235,642 shares held directly.
How many MRSN shares does Lowinger hold after this filing?
The filing shows 235,642 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this MRSN insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for MRSN
Earlier insider filings at MRSN
- Oct 4, 2024SEC Form 4 filed by Director Alleva Lawrence M
- Sep 13, 2024President, CEO Huber Martin H. Jr. converted options into 166,750 shares and sold $88,744 worth of shares (50,423 units at $1.76) (SEC Form 4)
- Jul 2, 2024SEC Form 4 filed by Director Alleva Lawrence M
- Jun 12, 2024SEC Form 4 filed by Director Hack Andrew A. F.
- Jun 12, 2024SEC Form 4 filed by Director Protopapas Anna
Keep researching MRSN
- MRSN insider tradesEvery buy and sale reported by Mersana Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Follow MRSN and get a push notification the moment its next story breaks.